Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | April 08, 2014

Key News and Technology at ACC.14

By Dave Fornell

The biggest news item from the American College of Cardiology (ACC) 63rd Annual Scientific Session was that a transcatheter aortic valve had 26 percent better survival in high-risk patients than surgical valve replacement. This is a big deal, as it shows the promise of transcatheter valve technology to eventually replace open-heart surgical procedures is not a theory out in left field. What is more impressive is the fact that the operators were given three patients to learn how to use the CoreValve device before their fourth and subsequent patients counted in the trial. Despite the relative inexperience with the device and procedure compared to cardiac surgeons, who in most cases have been performing valve replacements for a decade or longer, the fact that the new device outperformed surgery is very impressive. Read more on the trial or watch a video interview with one of the lead investigators.

The major disappointment at ACC.14 was the presentation of the SYMPLICITY HTN-3 renal denervation U.S. pivotal trial. The device used failed to reduce blood pressure a statistically significant amount over a sham procedure, calling into question the future of denervation technology. This session was packed solid with thousands of attendees, who wanted to hear the details and what the future might be for this technology. Read more on the trial or watch a video interview with one of the investigators.

A key late-breaking presentation for cardiac imaging was a combination of five trials that show coronary artery calcium scoring provides an early indication of a patient’s long-term risk for heart disease. Read more on the trial.

A key presentation in electrophysiology was the long-term results from the MADIT-CRT trial, which showed greatly improved outcomes and survival in heart failure patients with left bundle branch block. Read more on the trial.

I walked the exposition show floor and found several new, innovative technologies and on display. I also found some technologies that highlight trends in cardiology, including examples of how to achieve patient engagement and enterprise imaging. Watch the video “DAIC Editor’s Choice for Most Innovative New Technology.”

Related Content

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019
October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve re
COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019
October 3, 2019 – The three-year results from the...
Positive Safety, Efficacy Data Reported on AccuCinch Heart Failure Device
News | Heart Failure | September 27, 2019
Ancora Heart Inc. announced results from an interim analysis of heart failure patients treated in the CorCinch FMR...
Max and Debra Ernst Heart Center Opening at Beaumont Hospital, Royal Oak
News | Heart Failure | September 20, 2019
The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept. 30. It is dedicated to...
FDA Grants Fast Track Designation for Farxiga in Heart Failure
News | Heart Failure | September 18, 2019
AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...
Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Device Clinical Trial

The REDUCE LAP HF-II study will combine Corvia Medical's InterAtrial Shunt Device (IASD), pictured here, with physIQ's continuous monitoring platform to evaluate the device's efficacy in patients with heart failure. Image courtesy of Corvia Medical.

News | Heart Failure | September 12, 2019
Corvia Medical has sponsored and is actively enrolling patients in a heart failure (HF) device trial that, in addition...
 Tiny Wearable Cameras May Improve Quality of Life in Heart Failure Patients

Image courtesy of Amazon.com

News | Heart Failure | September 11, 2019
The ever-present devices that seem to track all our moves can be annoying, intrusive or worse, but for heart failure...
PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019
The angiotensin neprilysin inhibitor sacubitril/valsartan (Entresto) missed its primary endpoint of reducing total...
Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure
News | Heart Failure | September 09, 2019
AstraZeneca announced detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga (dapagliflozin) on...
Dapagliflozin, Forxiga, was found to help improve outcomes in heart failure patients with reduced ejection fraction (HFrEF) at ESC 2019. #ESC19 #ESC2019
News | Heart Failure | September 09, 2019
September 9, 2019 — The drug Dapagliflozin was found to reduce death and hospitalization in patients who have heart f
Overlay Init